Report data from the dose-finding portion of the KOURAGE 1 clinical program
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 22 Jan 2024
- Due
- 30 Sep 2024
- Delivered
- 12 Jun 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“A data readout from the dose-finding portion of the program is expected in the third quarter of 2024.”
What we found
Evidence strength A What the grades mean
Cara Therapeutics reported KOURAGE 1 Part A dose-finding data on June 12, 2024, ahead of the Q3 2024 deadline.
-
A Cara Therapeutics Q1 2024 Financial Results May update indicating results expected by end of Q2 2024
-
B Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Official announcement of dose-finding study results on June 12, 2024
Checked 22 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Language
- Expected (“expects”, “plans”)
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesGemini (Google) re-read the evidence blind and read it as “Superseded”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and reads it as “no_evidence”.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Cara Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-TVRD-000028 · Corrections policy